Work

Supplementary Figure Legends and Tables from A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure Legends and Supplementary Tables. Supplementary Table S1. Detailed clinical and diagnostic summary for a patient with ROS1-rearranged lung adenocarcinoma who developed acquired resistance to crizotinib and responded to cabozantinib. Supplementary Table S2. Next-generation sequencing results reveal a novel acquired ROS1 D2033N mutation in the CD74-ROS1 kinase domain.

DOI: 10.1158/1078-0432.22458389.v1

Authors: Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian J. Druker, Thomas O'Hare, Marc Ladanyi, Monika A. Davare

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361917142

Cites:

Cited by:

Related to: 10